Pentosan Polysulfate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Pentosan Polysulfate
- Pentosan Polysulfate: From an Unrecorded Original Indication to Primary Release Disorder of Platelets
Pentosan Polysulfate: From an Unrecorded Original Indication to Primary Release Disorder of Platelets
One-Sentence Summary
Pentosan polysulfate is a semi-synthetic sulfated polysaccharide (heparinoid) with weak anticoagulant/antiplatelet activity; no marketing authorization or approved indication is currently on file for this drug in the reference dataset. The TxGNN model predicts possible relevance to Primary Release Disorder of Platelets, but this signal is currently supported by zero clinical trials and zero publications — it is a pure knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record — no marketing authorization or approved indication text is present in the current dataset |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for pentosan polysulfate in this dataset. Based on general pharmacological knowledge captured in the evidence pack, the drug is a semi-synthetic sulfated polysaccharide (heparinoid) with weak anticoagulant/antiplatelet activity, which theoretically could influence platelet granule release pathways.
However, since no original indication is recorded for this drug and the drug carries no EU marketing authorization, there is no established clinical precedent to anchor a mechanistic comparison between “original use” and “predicted use.” The rationale supplied for this specific candidate acknowledges this gap directly: it notes the drug’s heparinoid activity as a theoretical, not demonstrated, link to platelet granule release disorders, with no direct mechanistic literature confirming the connection.
Given the complete absence of MOA documentation and original-indication context, this prediction should be treated as an unvalidated graph-similarity signal rather than a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No marketing authorizations are on record for this drug (Market Status: Not Marketed; Total Authorizations: 0).
Safety Considerations
Please refer to the SmPC for safety information. Note that since this drug has no recorded marketing authorization in the current dataset, no SmPC reference is currently available — this is flagged as a Blocking data gap (DG001: TFDA label warnings/contraindications) that prevents safety pre-screening (S1 stage).
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has Evidence Level L5 — the TxGNN score is high, but there are no supporting clinical trials or literature specific to pentosan polysulfate for this indication, and both the drug’s mechanism of action and its original approved use are undocumented in this dataset. Combined with the absence of any safety labeling data, there is insufficient basis to advance beyond initial screening (S0).
To proceed, the following is needed:
- Resolve the Blocking data gap (DG001): obtain TFDA/EMA label warnings and contraindications before any safety pre-screening
- Resolve the High-severity data gap (DG002): retrieve confirmed mechanism of action from DrugBank
- Establish the drug’s actual original/approved indication(s), since none are currently on record
- Seek mechanistic or preclinical studies directly linking pentosan polysulfate to platelet granule release physiology
- Given the drug’s anticoagulant/antiplatelet profile, any future development in a platelet release disorder should specifically evaluate bleeding-risk implications before proceeding
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.